Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)

PHASE2RecruitingINTERVENTIONAL

Enrollment

137

Participants

Timeline

Start Date

August 13, 2021

Primary Completion Date

February 13, 2026

Study Completion Date

August 13, 2029

Conditions

Breast CancerER Positive Breast Cancer

Interventions

DRUG

Letrozole 2.5mg

Aromatase Inhibitor

Trial Locations (2)

RECRUITING

Dartmouth Hitchcock Medical Center, Lebanon

RECRUITING

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors

lead

Dartmouth-Hitchcock Medical Center

OTHER